| pubmed-article:10369404 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10369404 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:10369404 | lifeskim:mentions | umls-concept:C0681867 | lld:lifeskim |
| pubmed-article:10369404 | lifeskim:mentions | umls-concept:C0920317 | lld:lifeskim |
| pubmed-article:10369404 | lifeskim:mentions | umls-concept:C0037004 | lld:lifeskim |
| pubmed-article:10369404 | lifeskim:mentions | umls-concept:C0012091 | lld:lifeskim |
| pubmed-article:10369404 | lifeskim:mentions | umls-concept:C0036043 | lld:lifeskim |
| pubmed-article:10369404 | lifeskim:mentions | umls-concept:C0205178 | lld:lifeskim |
| pubmed-article:10369404 | lifeskim:mentions | umls-concept:C0132515 | lld:lifeskim |
| pubmed-article:10369404 | pubmed:dateCreated | 1999-6-23 | lld:pubmed |
| pubmed-article:10369404 | pubmed:abstractText | Adverse events, particularly gastrointestinal, partially offset the therapeutic value of NSAIDs. The abilities of nimesulide to inhibit COX-2 preferentially and to exert other novel anti-inflammatory actions are consistent with good efficacy and safety. This is borne out by a double-blind multicentre comparison of nimesulide and diclofenac in 122 patients with acute shoulder, and by a meta-analysis of various nimesulide trials. At the end of the 14 day double-blind study, nimesulide was at least as effective as diclofenac (investigator ratings: good/very good in 79.0% of patients given nimesulide, and 78.0% with diclofenac; patient ratings: good/very good in 82.3 and 78.0% respectively). Four patients (6.5%) dropped out in the nimesulide group (two early recovery, one lack of effect, one adverse event), compared with 13 (21.7%) in the diclofenac group, due mainly to adverse events (P=0.003). Global tolerability was judged by the investigators to be good/very good in 96.8% of the nimesulide group compared with 72.9% of those given diclofenac. Judgements by the patients were 96.8 and 78.0% respectively. Both differences are highly significant statistically. The meta-analysis demonstrates that nimesulide given for 2 weeks is far more efficacious than placebo in treating osteoarthritis, and is at least comparable to other NSAIDs The benefit-risk ratio for nimesulide was better in all individual studies since 100 mg nimesulide twice daily was about equal to placebo in safety and tolerability, especially regarding gastrointestinal adverse events. | lld:pubmed |
| pubmed-article:10369404 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10369404 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10369404 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:10369404 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10369404 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10369404 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10369404 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10369404 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10369404 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10369404 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10369404 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10369404 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10369404 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10369404 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10369404 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10369404 | pubmed:month | May | lld:pubmed |
| pubmed-article:10369404 | pubmed:issn | 1462-0324 | lld:pubmed |
| pubmed-article:10369404 | pubmed:author | pubmed-author:WoberWW | lld:pubmed |
| pubmed-article:10369404 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10369404 | pubmed:volume | 38 Suppl 1 | lld:pubmed |
| pubmed-article:10369404 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10369404 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10369404 | pubmed:pagination | 33-8 | lld:pubmed |
| pubmed-article:10369404 | pubmed:dateRevised | 2007-9-6 | lld:pubmed |
| pubmed-article:10369404 | pubmed:meshHeading | pubmed-meshheading:10369404... | lld:pubmed |
| pubmed-article:10369404 | pubmed:meshHeading | pubmed-meshheading:10369404... | lld:pubmed |
| pubmed-article:10369404 | pubmed:meshHeading | pubmed-meshheading:10369404... | lld:pubmed |
| pubmed-article:10369404 | pubmed:meshHeading | pubmed-meshheading:10369404... | lld:pubmed |
| pubmed-article:10369404 | pubmed:meshHeading | pubmed-meshheading:10369404... | lld:pubmed |
| pubmed-article:10369404 | pubmed:meshHeading | pubmed-meshheading:10369404... | lld:pubmed |
| pubmed-article:10369404 | pubmed:meshHeading | pubmed-meshheading:10369404... | lld:pubmed |
| pubmed-article:10369404 | pubmed:meshHeading | pubmed-meshheading:10369404... | lld:pubmed |
| pubmed-article:10369404 | pubmed:meshHeading | pubmed-meshheading:10369404... | lld:pubmed |
| pubmed-article:10369404 | pubmed:meshHeading | pubmed-meshheading:10369404... | lld:pubmed |
| pubmed-article:10369404 | pubmed:meshHeading | pubmed-meshheading:10369404... | lld:pubmed |
| pubmed-article:10369404 | pubmed:meshHeading | pubmed-meshheading:10369404... | lld:pubmed |
| pubmed-article:10369404 | pubmed:meshHeading | pubmed-meshheading:10369404... | lld:pubmed |
| pubmed-article:10369404 | pubmed:meshHeading | pubmed-meshheading:10369404... | lld:pubmed |
| pubmed-article:10369404 | pubmed:meshHeading | pubmed-meshheading:10369404... | lld:pubmed |
| pubmed-article:10369404 | pubmed:meshHeading | pubmed-meshheading:10369404... | lld:pubmed |
| pubmed-article:10369404 | pubmed:meshHeading | pubmed-meshheading:10369404... | lld:pubmed |
| pubmed-article:10369404 | pubmed:meshHeading | pubmed-meshheading:10369404... | lld:pubmed |
| pubmed-article:10369404 | pubmed:meshHeading | pubmed-meshheading:10369404... | lld:pubmed |
| pubmed-article:10369404 | pubmed:meshHeading | pubmed-meshheading:10369404... | lld:pubmed |
| pubmed-article:10369404 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10369404 | pubmed:articleTitle | Comparative efficacy and safety of nimesulide and diclofenac in patients with acute shoulder, and a meta-analysis of controlled studies with nimesulide. | lld:pubmed |
| pubmed-article:10369404 | pubmed:affiliation | Institute for Clinical Research of MIM, München, Germany. | lld:pubmed |
| pubmed-article:10369404 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10369404 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:10369404 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:10369404 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:10369404 | pubmed:publicationType | Meta-Analysis | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10369404 | lld:pubmed |
